• Company
• No new news on reimb extension of Lorviqua for 4mths
• by Eo, Yun-Ho Oct 7, 2024 05:48am

• Company
• Camzyos’s reimbursement decision imminent
• by Moon, sung-ho Oct 4, 2024 04:38am

• Company
• Expectations rise for the reimbursement of Phesgo in Korea
• by Whang, byung-woo Oct 4, 2024 04:38am

• Company
• Biologics seek to expand indications…is approved for COPD
• by Son, Hyung Min Oct 4, 2024 04:38am

• Company
• "Importance of fungal infections TX amid COVID-19 spike"
• by Son, Hyung Min Oct 4, 2024 04:38am

• Company
• Imfinzi builds evidence for biliary tract cancer reimb
• by Whang, byung-woo Oct 2, 2024 05:49am

• Company
• Will the Imfinzi·Imjudo combo be reimb within the year?
• by Eo, Yun-Ho Oct 2, 2024 05:49am

• Company
• "Expanded scope for the newborn screening test"
• by Whang, byung-woo Oct 2, 2024 05:48am

• Company
• Jardiance generics prepare for final launch in Korea
• by Kim, Jin-Gu Sep 30, 2024 05:47am

• Company
• New myelodysplastic syndrome drug 'Reblozyl' lands Big 5 DC
• by Eo, Yun-Ho Sep 30, 2024 05:46am